Physician profile
Manisha Wadhwa
NPI 1851376354
$89,335.75
in general payments reported to CMS, 2019-2025
27 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,257 · 2021: $2,591 · 2022: $3,841 · 2023: $4,148 · 2024: $40K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $6,230 · Food and Beverage: $3,546 · Travel and Lodging: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,475.00 |
| Consulting Fee | $6,230.00 |
| Food and Beverage | $3,545.54 |
| Travel and Lodging | $2,130.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $36,076.59 | 2022-2025 | Lybalvi, Aristada |
| Abbvie INC. | $34,418.34 | 2021-2025 | Vraylar |
| Allergan, INC. | $15,939.73 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $348.53 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $297.39 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $295.50 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $235.11 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $233.34 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $180.99 | 2019-2025 | Trintellix |
| Lundbeck LLC | $174.68 | 2019-2025 | Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $136.05 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $127.23 | 2019-2024 | Invega, Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $123.44 | 2022-2025 | Auvelity |
| Corium, LLC | $122.67 | 2022-2025 | Azstarys |
| Neos Therapeutics, Lp | $113.56 | 2019-2024 | Adzenys Xr-Odt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $106.45 | 2019-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $89.23 | 2024-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $74.85 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $63.91 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $38.90 | 2019 | |
| Noven Therapeutics, LLC | $37.22 | 2024 | Xelstrym |
| Eisai INC. | $19.93 | 2021 | |
| Neuronetics, INC. | $19.12 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.84 | 2024 | Relexxii |
| Adlon Therapeutics L.P. | $16.99 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.07 | 2023 | Quviviq |
| Bausch Health US, LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Wadhwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.